These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 22722227)

  • 21. Antigen-specific therapies in multiple sclerosis.
    van Noort JM
    Biotherapy; 1998; 10(3):237-50. PubMed ID: 9559979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Therapeutic immunomodulation in neurology: from hope to reality. Exemplified by multiple sclerosis].
    Schluep M; Regli F
    Praxis (Bern 1994); 1995 Sep; 84(38):1021-4. PubMed ID: 7481299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contribution of peptides to multiple sclerosis research.
    Alcaro MC; Papini AM
    Biopolymers; 2006; 84(4):349-67. PubMed ID: 16518843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New therapeutic approaches for multiple sclerosis.
    De Jager PL; Hafler DA
    Annu Rev Med; 2007; 58():417-32. PubMed ID: 17217332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autoimmune pathogenesis of multiple sclerosis: role of autoreactive T lymphocytes and new immunotherapeutic strategies.
    Stinissen P; Raus J; Zhang J
    Crit Rev Immunol; 1997; 17(1):33-75. PubMed ID: 9034723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Multiple sclerosis: current immunological aspects].
    Cuevas-García C
    Rev Alerg Mex; 2017; 64(1):76-86. PubMed ID: 28188715
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro and in vivo models of multiple sclerosis.
    van der Star BJ; Vogel DY; Kipp M; Puentes F; Baker D; Amor S
    CNS Neurol Disord Drug Targets; 2012 Aug; 11(5):570-88. PubMed ID: 22583443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Experimental immunotherapies for multiple sclerosis.
    Martin R; McFarland H
    Springer Semin Immunopathol; 1996; 18(1):1-24. PubMed ID: 8984675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis.
    Martin R; McFarland HF
    Crit Rev Clin Lab Sci; 1995; 32(2):121-82. PubMed ID: 7598789
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What are exosomes and how can they be used in multiple sclerosis therapy?
    Pusic AD; Pusic KM; Kraig RP
    Expert Rev Neurother; 2014 Apr; 14(4):353-5. PubMed ID: 24552578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunomodulatory characteristics of mesenchymal stem cells and their role in the treatment of multiple sclerosis.
    Gharibi T; Ahmadi M; Seyfizadeh N; Jadidi-Niaragh F; Yousefi M
    Cell Immunol; 2015 Feb; 293(2):113-21. PubMed ID: 25596473
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical and pathological topics of multiple sclerosis].
    Lassmann H
    Rinsho Shinkeigaku; 2009 Nov; 49(11):715-8. PubMed ID: 20030193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Opportunistic infections and other risks with newer multiple sclerosis therapies.
    Berger JR; Houff S
    Ann Neurol; 2009 Apr; 65(4):367-77. PubMed ID: 19399841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel approaches and cutting edge immunotherapies in multiple sclerosis.
    Bauman TM; Kasper LH
    Front Biosci; 2004 Sep; 9():2302-22. PubMed ID: 15353289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis.
    Iglesias A; Bauer J; Litzenburger T; Schubart A; Linington C
    Glia; 2001 Nov; 36(2):220-34. PubMed ID: 11596130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunopathogenesis and immunotherapy of multiple sclerosis.
    Hemmer B; Nessler S; Zhou D; Kieseier B; Hartung HP
    Nat Clin Pract Neurol; 2006 Apr; 2(4):201-11. PubMed ID: 16932551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current immunotherapy of multiple sclerosis and future challenges: relevance of immune-mediated repair.
    Carrithers MD
    Curr Pharm Biotechnol; 2012 Jun; 13(8):1409-17. PubMed ID: 22339217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monoclonal antibodies: a target therapy for multiple sclerosis.
    Lorefice L; Fenu G; Frau J; Coghe G; Marrosu MG
    Inflamm Allergy Drug Targets; 2014; 13(2):134-43. PubMed ID: 24479836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies.
    Szczuciński A; Losy J
    Acta Neurol Scand; 2007 Mar; 115(3):137-46. PubMed ID: 17295707
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy of multiple sclerosis: the state of the art.
    Karussis D
    BioDrugs; 2013 Apr; 27(2):113-48. PubMed ID: 23423844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.